SEARCH

Current Edition

delivery

Halozyme, doubling down on a licensing strategy, buys a drug delivery biotech for nearly $1B

Dive Brief: Halozyme Therapeutics, a San Diego-based company whose business revolves around a type of drug delivery technology, announced Wednesday plans to expand its offerings …

Continue Reading →